Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...

Unionized workers at fast-growing South Korean CDMO Samsung Biologics kicked off a planned general strike on Friday, ...

Sun Pharma will acquire Organon for $11.75 billion. Astellas projects Xtandi sales to decline in fiscal year 2026. | Sun ...

Shortly after laying out $75 million upfront for Corstasis Therapeutics and its congestive heart failure edema drug Enbumyst, ...

Four years after gaining FDA approval for Auvelity to treat major depressive disorder (MDD), Axsome Therapeutics has tacked ...

Amgen CEO Robert Bradway has declared 2026 a “springboard year” for the California big biotech, in which the growth of its ...

Looking to clarify its expectations on manufacturer responses following inspections, the FDA earlier this year unveiled, for ...

Already the largest biopharma company in India, generics powerhouse Sun Pharma has doubled in size with its acquisition (PDF) ...

A surprise interim trial miss in ivonescimab’s closely watched Harmoni-3 trial has sent Summit Therapeutics’ shares tumbling, ...

As Ekterly nears the one-year anniversary of its FDA approval, Italy’s Chiesi Group is making moves to acquire the rare disease med and its developer, KalVista Pharmaceuticals. Chiesi has locked in an ...

Novartis CEO Vas Narasimhan is doubling down on his $5 billion peak sales projection for Pluvicto, even as the company has ...

Earlier this year, when the FDA asked Amgen to pull its rare disease drug Tavneos from the market, the California drugmaker ...